Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Editorial Expression of Concern: Recognition of the nonclassical MHC class I molecule H2-M3 by the receptor Ly49A regulates the licensing and activation of NK cells.

Nature immunology·2026

Same author

Correction: Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy.

The Journal of experimental medicine·2026

Same author

Author Correction: IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.

Nature communications·2024

Same author

TIGIT predominantly regulates the immune response via regulatory T cells.

The Journal of clinical investigation·2024

Same author

NK cell heparanase controls tumor invasion and immune surveillance.

The Journal of clinical investigation·2024

Same author

Correction: DX5/CD49b-Positive T Cells Are Not Synonymous with CD1d-Dependent NKT Cells.

Journal of immunology (Baltimore, Md. : 1950)·2024

Search research articles

Related Experiment Video

Updated: May 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Prospects for TIM3-Targeted Antitumor Immunotherapy.

Shin Foong Ngiow¹, Michele W L Teng, Mark J Smyth

¹Cancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Cancer Research

|October 20, 2011

Summary

Cancer immunotherapy shows promise with checkpoint inhibitors. This review explores the mechanism of anti-T-cell immunoglobulin and mucin domain 3 (TIM3) antibodies for cancer treatment, suggesting combination therapies.

More Related Videos

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1⁺ Tim-3⁺ CD8⁺ T Cells

Published on: February 8, 2018

Related Experiment Videos

Last Updated: May 28, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1⁺ Tim-3⁺ CD8⁺ T Cells

Published on: February 8, 2018

Area of Science:

Immunology
Oncology
Cancer Research

Background:

T-cell activation and proliferation are regulated by checkpoint proteins.
Monoclonal antibodies targeting CTLA-4 and PD-1 have shown success in cancer immunotherapy.
T-cell immunoglobulin and mucin domain 3 (TIM3) is an emerging inhibitory molecule target in oncology.

Purpose of the Study:

To investigate the mechanism of action of anti-TIM3 antibody therapy.
To evaluate anti-TIM3 antibody efficacy against established tumors in mice.
To explore rational combinations of immunotherapeutic agents.

Main Methods:

Utilized anti-TIM3 antibody in mouse models of spontaneous and experimental tumors.
Assessed tumor-specific T-cell responses, including activation, proliferation, and effector function.
Reviewed existing literature on T-cell checkpoint inhibitors.

Main Results:

Demonstrated the anti-tumor activity of anti-TIM3 antibody in established tumors.
Provided insights into the mechanistic basis of anti-TIM3 antibody action.
Highlighted the potential for combination immunotherapies.

Conclusions:

Anti-TIM3 antibody therapy is a promising approach for cancer treatment.
Combining anti-TIM3 with other agents may enhance anti-tumor immunity.
Further research into TIM3-targeted therapies is warranted.